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High-titer rapid 
response platform for 
epidemic preparedness
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Univercells exists to make biologics available and affordable to all –
Downsizing production infrastructure by intensification
Biologics for all – CAPEX is usually the first barrier
Source: Univercells
Old paradigm New paradigm
Centralized manufacturing for 
developed economies 
(e.g. USA, EU, Japan)
Distributed manufacturing for local 
markets
(e.g. Asia, Africa, Latin America)
Paradigm shift supported and promoted by all 
health-related NGOs and academics, i.e. WHO, 
BMGF, Wellcome Trust and MIT, UCL
By reducing the CAPEX & COGs, 
Univercells creates value for all:
> Manufacturer
– Affordable local facility
– Maintained margin
– Optimized pricing & market share 
increase
> Healthcare systems
– Increased number of treated 
patients
– Improved healthcare cost efficiency
– Autonomous supply for emerging 
economies
> Patients
– Affordable treatment
– Increased quality of life
3©2018 Univercells. All Rights reserved
Low-footprint, high-performance process
This is achieved by bringing out the best of technology innovations 
allowing a rapid deployment of low CAPEX/OPEX production facilities
Source: Univercells
All unit steps are chained into an 
integrated process, allowing
continuous operation from cell 
culture to clarification and capture
Use of high-density fixed-bed bioreactors 
operated in perfusion, and high-performance 
chromatography columns
Technology-driven affordability by applying chemical engineering rules 
> Dramatic reduction of 
CAPEX & OPEX
> Rapid deployment of 
multiproduct facilities 
with a capacity of:
– 5-40M doses/year
for Vaccines
– 50-500 kg/year for 
mAbs
ChainingIntensification
Value 
creation
4©2018 Univercells. All Rights reserved
Cell culture is performed in a bioreactor to significantly increase cell-
density, as a way to replace traditional manufacturing process 
Source: Univercells
Increase efficiency in cell culture – Single-use fixed-bed Bioreactor 
Traditional manufacturing
High cell-density bioreactor
4 RB* 20 RB 100 RB 600 RB ~7000 RB
Scale-out
of lab 
principle to 
industrial 
scale
Densification
of cell culture with 
fixed bed single-
use bioreactor
*Roller bottle
4 RB 20 RB
> Limited innovation in 
current vaccine 
manufacturing
– Over 80% of viral 
vaccines are still 
manufactured by 
the scaling out of 
lab-scale systems
> A 600m²  fixed-bed 
bioreactor replaces 
~7000 RB  in a 
volume of ~50L
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Univercells developed NevoLine™, a low-footprint micro-facility for viral 
production, chaining scale-X™ bioreactor with downstream processing
Viral production automated & integrated in cabinet
Source: Univercells
Culture
scale-X™ high-performance 
fixed-bed bioreactor
Purification
In-line clarification 
and purification
Inactivation
In contained 
cabinet
High performance single-
use fixed-bed bioreactor
> Intensification of cell culture & 
viral production process
> Drastic footprint reduction of 
bioreactor equipment
> Enables process chaining & 
containment
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NevoLine™ integrated fixed-bed bioreactor achieves high cell 
density & viral titers, delivering high-volume, low-cost viral production
Experimental data – sIPV production process
Source: Univercells
Viral Productivity Cell growth Purification 
> Reproducible cell growth
> Cell density at infection ~40M/ml
> PV3, ~ 40x increase
> PV2, ~25x increase
> Bioreactor size 
decreased by 25 to 40x 
compared to reference 
process
> Good HCP and HCD 
clearance 
> D-antigen recovery >90%
> One purification step 
with high impact on 
footprint and cost
> With current small scale yields, 
Univercells process would yield:
– ~1.6M doses/run purified
> With current small scale yields, 
Univercells process would yield:
– ~0.7M doses/run purified
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NevoLine™ micro-facility can be confined in BSL-2/3 pods, for a 
rapid deployment of high safety, low-footprint pod-based facilities
Source: Univercells
Miniaturization 
of equipment
Containment in 
isolator and pod
Production in 
low footprint facility
> Container-sized pod, BSL-1 to 
BSL-3 classification depending 
on pathogen
> Easily expandable
> Drastic CAPEX reduction
> Rapid deployment
1
2
3
~1,500m² with 4 micro-facility skids
> Production automated & 
contained in isolator
> Delivering low CoGs
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NevoLine™ achieves flexible & affordable viral production, 
enabling their rapid availability during epidemic outbreaks
Zoom on key benefits
Source: Univercells
Safety
> Automated, fully contained operations
> BSL2-3 compliant for safe production 
of viruses such as Ebola, Marburg 
fever, Lassa Fever
Flexibility & 
adaptability
> Broadly applicable to viral vaccines with minor hardware adaptations
> Facilitating process development of new vaccines
> Easily switch production from one product to the other
Cost-effectiveness
> Target CAPEX: ~€10-€20M
> Target CoGs trivalent sIPV: $0.15/dose
> Productivity on ~6m² footprint >10M 
doses/y
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These low-footprint and highly-contained production units are easily 
and rapidly deployable, offering adapted solutions for rapid response
Univercells platform applications for epidemic preparedness & response
Source: Univercells
Stockpiling1
Cost-effective source to generate rotating stockpile of 
pandemic vaccines
Install the micro-facility as preventive 
mothball extended manufacturing 
capacity, only to be reactivated during 
time of crisis
3
Stand-by 
production unit
2
Rapid 
deployement
Deploy quick-reaction units to manufacture emergency 
vaccines for emerging diseases
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“Humanity’s greatest advances 
are not in its discoveries, but in 
how those discoveries are applied 
to reduce inequity.” – Bill Gates
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